Tue, Sep 16, 2014, 5:37 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • jgmtruth jgmtruth Oct 15, 2013 12:15 PM Flag

    Gilead idelalisib some safety concerns.

    With idelalisib There were some adverse events during mid-stage studies, however, that could possibly raise some safety concerns. Severe reactions experienced by patients included pneumonia, dehydration, anemia, neutropenia, and thrombocytopenia.IMO ibrutinib much better with no safety issues.

    Sentiment: Strong Buy

122.18+1.14(+0.94%)Sep 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.